The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ALMS | -22.67% | N/A | N/A | -45% |
| S&P | +11% | +85.61% | +13.15% | +21% |
Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.07M | 0.0% |
| Gross Profit | $1.15M | 241.3% |
| Gross Margin | 55.66% | 0.0% |
| Market Cap | $415.22M | -17.7% |
| Market Cap / Employee | $2.26M | 0.0% |
| Employees | 184 | 68.8% |
| Net Income | -$110.75M | -18.9% |
| EBITDA | -$114.48M | -17.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $65.26M | -69.4% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $33.39M | 12.7% |
| Short Term Debt | $4.41M | 200.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -54.44% | 0.0% |
| Return On Invested Capital | -152.19% | 25.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$110.91M | -31.2% |
| Operating Free Cash Flow | -$110.91M | -32.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.23 | 1.28 | 0.97 | 0.86 | -164.59% |
| Price to Sales | 19.17 | 11.46 | 18.78 | - | |
| Price to Tangible Book Value | 1.23 | 1.28 | 0.97 | 0.96 | -172.17% |
| Enterprise Value to EBITDA | -1.74 | -1.68 | 1.64 | -0.66 | -74.30% |
| Return on Equity | -198.7% | -247.0% | -66.4% | -66.9% | - |
| Total Debt | $30.72M | $31.88M | $38.78M | $37.80M | 21.54% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
